Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness

Cardiac Electrophysiology Review
Vidal Essebag, Mark J Eisenberg

Abstract

Practice guidelines have expanded to include a new Class IIa recommendation for implantable cardiac defibrillator (ICD) use in patients post-myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) </=30% on the basis of the results of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II). Given that over 3 million patients in North America meet these criteria and over 400,000 additional patients will meet these criteria every year, the potential costs to the healthcare system are substantial and possibly prohibitive. The results of MADIT II must be interpreted in the context of other studies. The benefits of ICD therapy may vary substantially across subgroups of MADIT II patients. Studies of amiodarone suggest that it may be useful if used in addition to beta-blockers, and the relative value of this therapy compared to ICD therapy remains to be elucidated. Subgroups of MADIT II patients with QRS duration >0.12 seconds or LVEF </=25% appear to derive the greatest benefit from ICD therapy. Cost-effectiveness depends on the magnitude of benefit expected and will differ across subgroups of patients with different levels of risk. Better risk stratification strategies are needed to predict which...Continue Reading

Citations

Jan 13, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Massimo SantiniGiuseppe Boriani
Jan 9, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Jael Z AtaryMartin J Schalij
Dec 2, 2015·The Journal of Physiology·Riccardo ProiettiVidal Essebag

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Circulation Journal : Official Journal of the Japanese Circulation Society
Kaoru TannoMADIT II. The Multicenter Automtic Defibrillator Implantation Trial
Medical Decision Making : an International Journal of the Society for Medical Decision Making
James J BaileyTimothy R Church
Current Treatment Options in Cardiovascular Medicine
Stephen J. Hahn, Joseph M. Smith
© 2022 Meta ULC. All rights reserved